Brown Brothers Harriman & Co. Raises Stake in Haleon plc (NYSE:HLN)

Brown Brothers Harriman & Co. boosted its holdings in shares of Haleon plc (NYSE:HLN) by 80.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,653 shares of the company’s stock after acquiring an additional 6,084 shares during the period. Brown Brothers Harriman & Co.’s holdings in Haleon were worth $144,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Pitcairn Co. lifted its position in Haleon by 8.3% during the 3rd quarter. Pitcairn Co. now owns 250,187 shares of the company’s stock valued at $2,647,000 after acquiring an additional 19,085 shares during the period. Cerity Partners LLC lifted its position in Haleon by 23.4% during the 3rd quarter. Cerity Partners LLC now owns 576,533 shares of the company’s stock valued at $6,100,000 after acquiring an additional 109,311 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Haleon by 41.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 203,583 shares of the company’s stock valued at $2,154,000 after acquiring an additional 59,719 shares during the period. Banco Santander S.A. raised its holdings in Haleon by 54.0% in the third quarter. Banco Santander S.A. now owns 129,200 shares of the company’s stock worth $1,367,000 after buying an additional 45,300 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in Haleon in the third quarter worth about $1,794,000. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Stock Up 1.4 %

HLN opened at $9.73 on Thursday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The firm has a 50 day moving average price of $9.97 and a 200-day moving average price of $9.41. Haleon plc has a twelve month low of $7.89 and a twelve month high of $10.80. The stock has a market capitalization of $44.02 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 2.89 and a beta of 0.30.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Berenberg Bank assumed coverage on shares of Haleon in a report on Tuesday, August 6th. They issued a “buy” rating for the company. Morgan Stanley lifted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a report on Friday, September 20th. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Finally, UBS Group raised shares of Haleon to a “strong-buy” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.